Drug Trial Radar · NCT00779103
Histrelin Subcutaneous Implant in Children With Central Precocious Puberty
Last checked: Nov 20, 2026Latest source record: Jan 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Sep 2004
Primary completion
Aug 2011
Study completion Apr 2012
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to follow and collect additional medical and developmental information on children after histrelin subcutaneous implant therapy is discontinued.
Conditions
- Central Precocious Puberty
Interventions
Histrelin Subcutaneous ImplantDrug
histrelin subcutaneous 50 mg implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Luteinizing Hormone (LH)Time frame: Baseline - 6 Months Post Last Implant
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.